Immune modulation by chondroitin sulfate and its degraded disaccharide product in the development of an experimental model of multiple sclerosis

Journal of Neuroimmunology

Volumn 223, Issue 1-2, 2010, Pages 55-64

  Zhou, Juhua ^a   Nagarkatti, Prakash ^a   Zhong, Yin ^a   Nagarkatti, Mitzi ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cell migration; Chondroitin sulfate; Cytokines; EAE MS; Immune modulation

Indexed keywords

CARBOHYDRATE DERIVATIVE; CHONDROITIN SULFATE; DISACCHARIDIC DEGRADATION PRODUCT OF CHONDROITIN SULFATE PROTEOGLYCAN; INTERLEUKIN 17; INTERLEUKIN 23; STAT4 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISACCHARIDES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; PEPTIDE FRAGMENTS; PROTEOCHONDROITIN SULFATES; TOXOIDS;

EID: 77953541191     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.04.002     Document Type: Article

References (48)

1. Akiyama H., Sakai S., Linhardt R.J., Goda Y., Toida T., Maitani T. Chondroitin sulphate structure affects its immunological activities on murine splenocytes sensitized with ovalbumin. Biochem. J. 2004, 382:269-278.
2. Appay V., Dunbar P.R., Callan M., Klenerman P., Gillespie G.M., Papagno L., Ogg G.S., King A., Lechner F., Spina C.A., Little S., Havlir D.V., Richman D.D., Gruener N., Pape G., Waters A., Easterbrook P., Salio M., Cerundolo V., McMichael A.J., Rowland-Jones S.L. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 2002, 8:379-385.
3. Aranami T., Yamamura T. Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol. Int. 2008, 57:115-120.
4. Baaten B.J., Li C.R., Deiro M.F., Lin M.M., Linton P.J., Bradley L.M. CD44 regulates survival and memory development in Th1 cells. Immunity 2010, 32:104-115.
5. Baeurlea S.A., Kiselevb M.G., Makarovab E.S., Nogovitsinb E.A. Effect of the counterion behavior on the frictional-compressive properties of chondroitin sulfate solutions. Polymer 2009, 50:1805-1813.
6. Bruyere O., Reginster J.Y. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007, 24:573-580.
7. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., Bradley J.D., Bingham C.O., Weisman M.H., Jackson C.G., Lane N.E., Cush J.J., Moreland L.W., Schumacher H.R., Oddis C.V., Wolfe F., Molitor J.A., Yocum D.E., Schnitzer T.J., Furst D.E., Sawitzke A.D., Shi H., Brandt K.D., Moskowitz R.W., Williams H.J. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 2006, 354:795-808.
8. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev., Immunol. 2008, 8:337-348.
9. Dutton R.W., Bradley L.M., Swain S.L. T cell memory. Annu. Rev. Immunol. 1998, 16:201-223.
10. + T cells in experimental autoimmune encephalomyelitis. Am. J. Pathol. 2008, 173:411-422.
11. Engelhardt B., Martin-Simonet M.T., Rott L.S., Butcher E.C., Michie S.A. Adhesion molecule phenotype of T lymphocytes in inflamed CNS. J. Neuroimmunol. 1998, 84:92-104.
12. Gotte M., Yip G.W. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006, 66:10233-10237.
13. Guan H., Nagarkatti P.S., Nagarkatti M. Role of CD44 in the differentiation of Th1 and Th2 cells: CD44-deficiency enhances the development of Th2 effectors in response to sheep RBC and chicken ovalbumin. J. Immunol. 2009, 183:172-180.
14. Hochberg M.C., Clegg D.O. Potential effects of chondroitin sulfate on joint swelling: a GAIT report. Osteoarthritis Cartilage 2008, 16(Suppl 3):S22-24.
15. Holmoy T. Immunopathogenesis of multiple sclerosis: concepts and controversies. Acta Neurol. Scand. Suppl. 2007, 187:39-45.
16. Kaplan M.H., Sun Y.L., Hoey T., Grusby M.J. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996, 382:174-177.
17. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:566-573.
18. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
19. Marhaba R., Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J. Mol. Histol. 2004, 35:211-231.
20. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., Cua D.J. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 2007, 8:1390-1397.
21. Merkur'eva R.V., Bukhtoiarova F.G. Glycosaminoglycans in blood serum of patients with rheumatoid arthritis. Vopr. Med. Khim. 1976, 22:291-296.
22. Monfort J., Martel-Pelletier J., Pelletier J.P. Chondroitin sulphate for symptomatic osteoarthritis: critical appraisal of meta-analyses. Curr. Med. Res. Opin. 2008, 24:1303-1308.
23. Monfort J., Pelletier J.P., Garcia-Giralt N., Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann. Rheum. Dis. 2008, 67:735-740.
24. Morris J.D., Smith K.M. Chondroitin sulfate in osteoarthritis therapy. Orthopedics 2009, 32.
25. Nagelkerken L. Role of Th1 and Th2 cells in autoimmune demyelinating disease. Braz. J. Med. Biol. Res. 1998, 31:55-60.
26. Nishikomori R., Usui T., Wu C.Y., Morinobu A., O'Shea J.J., Strober W. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling. J. Immunol. 2002, 169:4388-4398.
27. Penkowa M., Hidalgo J. Metallothionein treatment reduces proinflammatory cytokines IL-6 and TNF-alpha and apoptotic cell death during experimental autoimmune encephalomyelitis (EAE). Exp. Neurol. 2001, 170:1-14.
28. Pure E., Assoian R.K. Rheostatic signaling by CD44 and hyaluronan. Cell. Signal. 2009, 21:651-655.
29. Rolls A., Avidan H., Cahalon L., Schori H., Bakalash S., Litvak V., Lev S., Lider O., Schwartz M. A disaccharide derived from chondroitin sulphate proteoglycan promotes central nervous system repair in rats and mice. Eur. J. NeuroSci. 2004, 20:1973-1983.
30. Rolls A., Cahalon L., Bakalash S., Avidan H., Lider O., Schwartz M. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration. FASEB J. 2006, 20:547-549.
31. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 2004, 22:745-763.
32. Sawitzke A.D., Shi H., Finco M.F., Dunlop D.D., Bingham C.O., Harris C.L., Singer N.G., Bradley J.D., Silver D., Jackson C.G., Lane N.E., Oddis C.V., Wolfe F., Lisse J., Furst D.E., Reda D.J., Moskowitz R.W., Williams H.J., Clegg D.O. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum. 2008, 58:3183-3191.
33. Segal B.M. Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease. Curr. Allergy Asthma Rep. 2003, 3:86-93.
34. Singh N.P., Hegde V.L., Hofseth L.J., Nagarkatti M., Nagarkatti P. Resveratrol (trans-3, 5, 4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol. Pharmacol. 2007, 72:1508-1521.
35. Skarica M., Wang T., McCadden E., Kardian D., Calabresi P.A., Small D., Whartenby K.A. Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis. J. Immunol. 2009, 182:4192-4199.
36. + T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J. Neurosci. Res. 2005, 79:680-693.
37. Sprent J., Surh C.D. T cell memory. Annu. Rev. Immunol. 2002, 20:551-579.
38. Takatori H., Kanno Y., Chen Z., O'Shea J.J. New complexities in helper T cell fate determination and the implications for autoimmune diseases. Mod. Rheumatol. 2008, 18:533-541.
39. Thierfelder W.E., van Deursen J.M., Yamamoto K., Tripp R.A., Sarawar S.R., Carson R.T., Sangster M.Y., Vignali D.A., Doherty P.C., Grosveld G.C., Ihle J.N. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996, 382:171-174.
40. Uebelhart D. Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage 2008, 16(Suppl 3):S19-21.
41. Uebelhart D., Knols R., de Bruin E.D., Verbruggen G. Treatment of knee osteoarthritis with oral chondroitin sulfate. Adv. Pharmacol. 2006, 53:523-539.
42. Vangsness C.T., Spiker W., Erickson J. A review of evidence-based medicine for glucosamine and chondroitin sulfate use in knee osteoarthritis. Arthroscopy 2009, 25:86-94.
43. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
44. Villarroya H., Marie Y., Ouallet J.C., Le Saux F., Tchelingerian J.L., Baumann N. Expression of TNF alpha in central neurons of Lewis rat spinal cord after EAE induction. J. Neurosci. Res. 1997, 49:592-599.
45. Volpi N. The pathobiology of osteoarthritis and the rationale for using the chondroitin sulfate for its treatment. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2004, 4:119-127.
46. Wang J.Y., Roehrl M.H. Glycosaminoglycans are a potential cause of rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14362-14367.
47. Wiemann B., Van G.Y., Danilenko D.M., Yan Q., Matheson C., Munyakazi L., Ogenstad S., Starnes C.O. Combined treatment of acute EAE in Lewis rats with TNF-binding protein and interleukin-1 receptor antagonist. Exp. Neurol. 1998, 149:455-463.
48. + T cells for the development of experimental autoimmune encephalomyelitis (EAE). J. Autoimmun. 2001, 17:17-25.